Business Context and Reporting Period
Company: TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.)
Filing Date: October 18, 2024
Event: Completion of a reverse merger with TuHURA Biosciences, Inc. (the "Merger"). Kintara Therapeutics, Inc. changed its name to TuHURA Biosciences, Inc. and adopted a new ticker symbol, "HURA," on the Nasdaq Capital Market.
Corporate Actions: A 1-for-35 reverse stock split was effected immediately prior to the Merger. The Company changed its fiscal year-end from June 30 to December 31.
Key Financial Metrics and Capital Structure
Share Capital: Approximately 42,030,336 shares of common stock issued and outstanding immediately following the Merger.
Ownership Structure: Former TuHURA stockholders own approximately 97.15% of the Company on a fully-diluted basis. Former Kintara stockholders own approximately 2.85%.
Contingent Value Rights (CVRs): Former Kintara stockholders received CVRs entitling them to approximately 1,539,918 shares of common stock if specific clinical milestones are met by December 31, 2025.
Financial Statements: This 8-K does not contain specific revenue, profit, or cash flow figures for the current period. Unaudited pro forma financial information for the six months ended June 30, 2024, and the year ended December 31, 2023, is incorporated by reference in Exhibit 99.4.
Material Changes and Transaction Details
- Merger Completion: Kintara merged with a subsidiary of TuHURA, with TuHURA surviving as a wholly-owned subsidiary. The business focus is now primarily TuHURA's clinical-stage immuno-oncology operations.
- Waiver Agreement: The parties waived the requirement for Kintara to deliver a specific Parent Closing Net Cash amount and the requirement for TuHURA to deliver Lock-Up Agreements representing 50% of shares. TuHURA delivered Lock-Up Agreements representing approximately 34% of shares.
- Executive Leadership: Robert E. Hoffman resigned from all Kintara offices. James Bianco, M.D. was appointed CEO; Daniel Dearborn was appointed CFO; and Dennis Yamashita, Ph.D. was appointed Chief Scientific Officer.
- Board Composition: The Board was reconstituted with five members: Robert E. Hoffman (Kintara representative) and James Manuso, James Bianco, Alan List, and George Ng (TuHURA representatives).
Outlook, Risks, and Unusual Items
Strategic Focus: The Company is developing personalized cancer vaccines (IFx-2.0, IFx-3.0) and bi-functional antibody drug conjugates (ADCs) targeting myeloid-derived suppressor cells (MDSCs).
Clinical Milestones and CVRs:
- REM-001 (Kintara Asset): The Company will continue an NIH-sponsored study for REM-001 in cutaneous metastatic breast cancer. Achievement of the CVR Milestone requires enrolling 10 patients and completing 8 weeks of follow-up by December 31, 2025, to determine if a lower dose is effective. The Company will expend up to $700,000 (plus available NIH grants) to pursue this.
- IFx-2.0: The Company is working to resolve a partial clinical trial hold from the FDA regarding chemistry, manufacturing, and controls (CMC) for a Phase 3 trial in Merkel cell carcinoma. Initiation is targeted for Q1 2025, pending FDA acceptance of in-mixing studies and potency assays.
Risks:
- Failure to satisfy FDA requirements for the IFx-2.0 Phase 3 trial.
- Failure to achieve the REM-001 milestone, resulting in no payout for CVR holders.
- Standard biopharmaceutical risks including clinical trial failure, regulatory delays, and capital requirements.
Investor Verification Checklist
- Verify the status of the FDA partial clinical trial hold for IFx-2.0 and the timeline for Phase 3 initiation.
- Review the specific terms of the Contingent Value Rights (CVR) Agreement (Exhibit 10.1) regarding the REM-001 milestone.
- Examine the Unaudited Pro Forma Condensed Financial Information (Exhibit 99.4) for combined liquidity and debt positions.
- Confirm the details of the Lock-Up Agreements and the 34% coverage provided by TuHURA stockholders.
- Monitor the progress of the NIH-sponsored REM-001 study enrollment.